

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 August 2001 (02.08.2001)

PCT

(10) International Publication Number
WO 01/54674 A1

(51) International Patent Classification⁷: **A61K 9/70**

(21) International Application Number: **PCT/EP01/00870**

(22) International Filing Date: 26 January 2001 (26.01.2001)

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
MI2000A000095 26 January 2000 (26.01.2000) **IT**

(71) Applicant (for all designated States except US): **F.T. HOLDINGS S.A.** [LU/LU]; 207, route d'Arlon, L-1150 Luxembourg (LU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ROVERSI, Francesco** [IT/CH]; Via S. Francini 40, CH-6900 Lugano (CH). **CILURZO, Francesco** [IT/IT]; Viale Pasubio, 6, I-20154 Milano (IT).

(74) Agent: **GERVASI, Gemma**; Notarbartolo & Gervasi S.p.A., Corso di Porta Vittoria, 9, I-20122 Milano (IT).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/54674 A1

(54) Title: **PATCH FOR LOCAL AND TRANSDERMAL ADMINISTRATION OF ACTIVE INGREDIENTS CONTAINING AN- IONIC OR ELECTRON-ATTRACTING GROUPS**

(57) Abstract: A patch for local and transdermal administration of active ingredients containing anionic or electron attracting groups comprising: a) a prevalently aqueous polymeric matrix containing said active ingredient, whose polymer is selected from the group consisting of: a-1) an anionic copolymer of methacrylic acid with a methacrylate ester with a C₁-C₁₀ linear or branched alcohol, a-2) a cationic copolymer of methacrylic acid with a C₁-C₁₀ linear or branched alcohol containing a tertiary aminic group, and a neutral methacrylate ester with a C₁-C₁₀ linear or branched alcohol, said polymeric matrix further comprising: a3) high molecular weight polyvinylpyrrolidone, a4) a plasticizer, b) a backing layer which the matrix is adhered to, c) a protective film removable at the moment placed on said polymeric matrix (a). This patch allows to release effective concentration of said active ingredients and may be removed without leaving residue on the protective film or on the skin.

PATCH FOR LOCAL AND TRANSDERMAL ADMINISTRATION OF ACTIVE INGREDIENTS CONTAINING ANIONIC OR ELECTRON-ATTRACTING GROUPS

FIELD OF THE INVENTION

- 5 A patch for administering by local and transdermal route active ingredients containing anionic or electron-attracting groups, makes it possible to obtain effective concentrations of said active ingredients and is easy to use.

STATE OF THE ART

- 10 Patches are useful both for transdermal administration and for local administration of active principles.

Administration by transdermal route has over the years become increasingly appreciated, in that it enables effective blood levels to be obtained for more prolonged intervals of time.

- 15 As compared to what occurs in the case of creams and ointments, local administration made with patches enables precise doses of the active principle, its controlled release, as well as the delimitation and protection of the area of administration.

- 20 The problems connected to this type of administration regard both the stability of the active ingredient and its capacity for being effectively released by the pharmaceutical form. On the other hand, the said pharmaceutical form must be manageable for use, i.e., provided with good adhesiveness and detachable both from the protective film and from the skin without leaving any residue.

- 25 US 5,296,512 (in the name of Rohm GmbH Chemische Fabrik) describes transdermal pharmaceutical forms which are removable with water and consist of a backing layer coated with mono-ethylenically unsaturated mono-carboxylic acid or di-carboxylic acid and of at least one ester of (meth)acrylic acid copolymer. This pharmaceutical form presents, however, drawbacks of a cohesive nature such as to be prejudicial to their entry on the market. The aqueous polymeric systems, like that disclosed in this patent, have been until now proposed by the manufacturers,
30 mainly to make the adhesive layer in bilayered patches; their use in order to achieve controlled drug release is poorly investigated also because of their low

- cohesive properties. It is therefore interesting to improve the technological characteristic of the dry matrix, such as adhesive properties and drug release, by adding to the polymeric mixture other excipients, enhancing the cohesive properties of said polymeric systems. For this purpose the most conventional approach is to introduce, into the polymeric system, bivalent ions, such as zinc, usually in the form of zinc sulphate, which act as cross-linking agents. However, the addition of even small quantities of zinc sulphate causes aggregation of the polymeric chains on account of the strong interaction between the carboxyl groups of the polymer and the ion.
- A second approach to solving the above problem is the addition of a second polymer to the matrix, but in view of the plethora of compounds that may be used in this way (polycarboxymethylenes, hydroxymethyl celluloses, hydroxypropyl celluloses, carboxymethyl celluloses, arabic gum, Tragacanth or guar gum, polyvinyl pyrrolidones, etc.), the solution of the problem is far from immediate also because, in addition to the problems connected to the compatibility with the other polymers present and the characteristics of adhesiveness and cohesion sought, it is necessary to take into account the compatibility of this new component with the active principles.

SUMMARY OF THE INVENTION

- There has now been surprisingly found a patch for local and transdermal administration of active ingredients containing anionic or electron-attracting groups which is able to obtain effective concentrations of active ingredient and afford both good adhesiveness and an optimal detachment both from the protective film and from the skin.
- Consequently, the present invention relates to a patch for local and transdermal administration of an active ingredient having at least one anionic or electron-attracting group and pharmaceutically acceptable salts thereof comprising:
- a) a prevalently aqueous polymeric matrix containing said active ingredient, whose polymer is selected from the group consisting of:
 - a-1) an anionic copolymer of methacrylic acid with a methacrylate ester with a C_1 - C_{10} linear or branched alcohol,

a-2) a cationic copolymer of methacrylic acid with a C₁-C₁₀ linear or branched alcohol containing a tertiary aminic group, and a neutral methacrylate ester with a C₁-C₁₀ linear or branched alcohol,

said polymeric matrix further comprising

- 5 a3) high molecular weight polyvinylpyrrolidone,
a4) a plasticizer,

b) a backing layer which the matrix is adhered to,

c) a protective film removable at the moment placed on said polymeric matrix (a).

DESCRIPTION OF THE FIGURES

- 10 Figure 1 shows the *in vitro* permeation graph for Formulation 2 of Example 1 containing Flurbiprofen as compared to the commercial product Transact™.

Figure 2 shows the *in vitro* permeation graph for Formulation 1 of Example 1 containing Ketoprofen as compared to the commercial product Fastum Gel™.

- Figure 3 shows the *in vitro* permeation graph for Formulation 3 containing sodium
15 Diclofenac of Example 3 as compared to the commercial product Diclorem Tissugel™.

In ordinates of said Figures reported is the amount of permeated active ingredient expressed as µg/cm², and in abscissae reported is the time expressed in hour.

DETAILED DESCRIPTION OF THE INVENTION

- 20 The anionic copolymer of type (a1) or cationic copolymer of type (a2) have preferably a molecular weight ranging from 80,000 to 500,000, more preferably from 100,000 to 300,000.

- According a preferred embodiment the copolymer (a1) is selected from the copolymer of methacrylic acid and methylmethacrylate and the copolymer of
25 methacrylic acid and ethylmethacrylate, whereas the cationic copolymer (a2) is selected from the copolymers of dimethylaminoethylmethacrylate with methylmethacrylate and dimethylaminoethylmethacrylate with butylmethacrylate, and mixtures thereof.

- According to a more preferred embodiment of the present invention the specific
30 product already available on the market with the commercial name EUDRAGIT™ L, and specifically EUDRAGIT™ L100, which is in the form of a white fine

powder, is used as the methacrylic acid -methymethacrylate copolymer belonging to the aforementioned class (a1). This product is characterised by having a ratio of free carboxylic groups/ester groups being approximately 1:1 and an average molecular weight of 135000. Analogously according to a more preferred embodiment, the product sold with the commercial name EUDRAGITTM L-100-55, and in the form of a white fine powder is used as the methacrylic acid -ethylmethacrylate copolymer belonging to class (a1). This product is characterised by having the ratio of free carboxylic acid/ester groups is about 1/1. Said product has an average molecular weight of 250,000. More preferably a mixture of copolymer dimethylaminoethylmethacrylate - methylmethacrylate and copolymer dimethylaminoethylmethacrylate - butylmethacrylate is used as the polymeric cation belonging to class (a2) has an average molecular weight of 150,000 and is available on the market with the trademark EUDRAGITTME, and in particular EUDRAGITTM E100, which is in the form of white to yellow tinged granules.

For high molecular weight polyvinylpyrrolidone we mean a polyvinylpyrrolidone having an average molecular weight ranging from 300,000 to 1,350,000. According to particularly preferred embodiments the product available on the market with the commercial name: KOLLIDON 90TM F sold by BASF and characterised by having an average molecular weight of 1,100,000, or the product PVP33000 sold by Carlo Erba having an average molecular weight of 335,000 is used as polyvinylpyrrolidone.

Examples of plasticizing agents useful for the purposes of the present invention are acetyl tributyl citrate, tributyl citrate, glycerine, propylene glycol, polyethylene glycols (PEGs) having various molecular weights, phthalates and triethyl citrate. Optionally, the patch of the present invention may contain non-ionic and anionic surfactants.

The patch of the present invention is suitable for vehicling active ingredients containing anionic groups or electron attracting groups. These active ingredients belong preferably to the following therapeutical classes: non-steroidal anti-inflammatory drugs, such as Ketoprofen, Flurbiprofen, Ibuprofen, Naproxen,

Indomethacin, Diclofenac Piroxicam, and salts thereof, muscle relaxants such as Thiocolchicoside, antihypertensive drug such as dihydropyridine, and in particular Nifedipine, Clonidine, analgesics such as Fentanyl, and local anaesthetics such as Lidocaine, antianginal drugs such as Nitroglycerin.

- 5 The active ingredients contained in the matrix of the patch of the invention are able to be vehicled locally and transdermally *in vivo* with results at least comparable to those of other transdermal systems at present commercially available, as will be shown in what follows, whilst the cohesiveness of the matrix is altogether excellent.
- 10 Optionally, it is possible to add to the matrix of the patch of the invention enhancers without these adversely affecting the degree of cohesion of the matrix itself. Amongst the enhancers the following may be cited as examples: Transcutol (diethylen glycolmonoethylether), propylene glycol, polyhydroxylated castor oil, polyethylene glycols of different molecular weights, unsaturated and saturated
- 15 acids and esters thereof such as isopropylmyristate, Lauroglycol (propylenglycol monolaurate or dilaurate), Labrafil (macrogol glyceride ester with oleic acid), Labrasol (macrogol glyceride with caprylic acid), polysorbates such as Tween®, and Span® and in particular Span® 80, polyoxyethylenalcohols such as Brij®, and in particular Brij® 58 (cetomacrogol 1000), and terpenes, such as limonene
- 20 menthol, eucalyptol.

In the patch according to the backing layer (b) is preferably made of woven fabric, non-woven fabric, polymeric film and foaming material.

The patch according to the present invention may be prepared as follows.

- A prevalently aqueous solution of the copolymers of the aforementioned class (a1)
- 25 or (a2) is prepared. In case the copolymer of class (a1) is used containing free carboxyl groups, it is advisable, for the purpose of obtaining its dissolution, to add an aqueous solution of a hydroxide of an alkaline or alkaline-earth metal, preferably sodium hydroxide or potassium hydroxide. Once a homogeneous solution has been obtained, there is to be added, at least one plasticizing agent.
- 30 Finally, a solution of polyvinylpyrrolidone (PVP) is added to the above solution. Then, after undergoing stirring the solution is left to stand to enable removal of

any air that may be trapped in it.

The PVP is used in concentrations ranging from 5 to 50 wt%, and in aqueous solution and/or in solution with an appropriate water-mixable organic solvent. All the other solutions useful for preparation of the matrix of the invention, including
5 the one containing the active principle, are water solutions, optionally containing up to a maximum of 45 wt% of a water-mixable organic solvent.

The mixture thus obtained is spread and dried onto the protective film (c), and finally made to adhere to the backing layer (b).

The active ingredient in aqueous solution referred to above may be added to a
10 solution of the copolymer (a1) or (a2), or alternatively to that of the PVP before the latter is mixed with the solution of the polymer or copolymer. The alternative depends upon the characteristics of solubility of the active principle.

The temperature at which the entire process takes place ranges from 20°C to 80°C according to the type of polymer or copolymer used.

15 As regards the dried matrix, this contains from 1 to 15 wt% of active principle, preferably from 2 to 6%, and from 2 to 200 wt% of PVP with respect to the copolymer weight, preferably from 30 to 100 wt%.

The plasticizing agent is contained in an amount of 5-200 wt% with respect to the copolymer weight.

20 The surfactant is contained in an amount of 0.1-100 wt% with respect to the copolymer weight.

The enhancers are contained in an amount of 1-150 wt% with respect to the polymer or copolymer.

The invention will now be illustrated in greater detail by the following examples.

25

EXAMPLE 1

A. Formulation 1

Composition of the matrix

Ketoprofen	1.9	g
Eudragit L	10.7	g
Water	16.4	g

Sodium hydroxide	1.9	g
Water	19.2	g
PEG 400	16.1	g
Glycerine	7.0	g
Polyvinyl pyrrolidone 33000 (PVP)	5.4	g
Water	21.4	g

Process of fabrication

Solution A

Eudragit L was dispersed in water under propeller stirring at a speed of 100 rpm for 10 minutes. Prepared apart was the solution of sodium hydroxide, which was added as fast as possible to the suspension of Eudragit L, and the speed of the stirrer was increased gradually up to 250 rpm. After approximately 5 minutes a homogeneous solution was obtained to which PEG 400 and glycerine were added. The resulting system was kept under stirring at the same speed for a further 15 minutes and then left to stand up to complete removal of any air that might have been entrapped therein.

Solution B

The PVP was added slowly to the water heated to 50°C and kept under stirring with a magnetic stirrer. Any water that might have evaporated was restored after cooling to room temperature.

Addition of the active principle

The active ingredient Ketoprofen was added to solution A, which had been heated to 40°C, and the system was kept under magnetic stirring up to complete dissolution of the Ketoprofen (approximately 15 minutes). At the end of the process the solution B previously heated to the same temperature was added, and the resulting dispersion was further stirred for 15 minutes. Any water that might have evaporated was restored. The resulting polymeric system was left to stand, up to complete removal of any air that might have been englobed therein, before being used.

B. Formulation 2

The procedure was as for point A, with the same components and amounts,

but replacing the Ketoprofen with 1.9 g of Flurbiprofen.

Formulations 1 and 2 were used for preparing patches according to the following specifications:

Backing layer	Artificial silk
Protective film:	siliconized paper
Spreading on the protective film and drying of the matrix were performed with a Matis spreading machine – Model: LTE-S	
Rate of spreading:	1m/min
Drying time:	15 min
Drying temperature:	60°C with horizontal air circulation
Distance between knife and protective film:	300 µm
At the end of the drying process, the matrix dried on siliconized paper was made to adhere to the backing layer.	

5

EXAMPLE 2

Formulation 3

Composition of the matrix

Sodium Diclofenac	1.8	g
Eudragit L	10.35	g
Water	15.9	g
Sodium hydroxide	1.85	g
Water	18.6	g
PEG 400	15.5	
Glycerine	6.8	g
Polyvinyl pyrrolidone 33000 (PVP)	5.2	g
Methanol	20.6	g
Tween 80	0.6	g
Transcutol	2.8	g

Process of fabrication

Solution A

Eudragit L was dispersed in water under propeller stirring at a speed of 100 rpm for 10 minutes. Prepared apart was the solution of sodium hydroxide, which was
5 added as fast as possible to the suspension of Eudragit L, and the speed of the stirrer was increased gradually up to 250 rpm. After obtaining a homogeneous solution, PEG 400 and glycerine were added. The resulting system was kept under stirring at the same speed for a further 15 minutes and then left to stand up to complete removal of any air that might have been englobed therein.

10

Solution B

The PVP was added slowly to the methanol and kept under stirring with a magnetic stirrer up to complete solubilization. Any methanol that might have evaporated was restored. Next Tween 80 and Transcutol were added.

15 *Addition of the active principle*

The active ingredient sodium Diclofenac was added to solution B, and the system was kept under magnetic stirring for 15 minutes. At the end of the process, solution A was added, and the resulting dispersion was further stirred for 15 minutes. Any water that might have evaporated was restored. The resulting
20 polymeric system was left to stand, up to complete removal of any air that might have been englobed therein, before being used.

Formulation 3 was used for preparing a patch according to the following specifications:

Backing layer:	PVC
Protective film:	siliconized paper
Spreading on the protective film and drying of the matrix were performed with a Matis spreading machine – Model LTE-S	
Rate of spreading:	1m/min
Drying time:	12 min
Drying temperature:	50°C
Distance between knife and protective film:	300 μ m
At the end of the drying process, the matrix dried on the siliconized paper was made to adhere to the backing layer.	

EXAMPLE 3

Proceeding as described in Example 1, a series of formulations without, however,
 5 the active ingredient and having the following composition in grams was prepared:

Formulation	Eudragit L	Glycerine	PEG	NaOH	PVP
4	33.07	19.48	40.33	5.95	2.91
5	29.13	19.03	43.69	5.24	5.66
6	28.3	18.49	42.45	5.09	9.8
7	27.06	17.68	40.59	4.87	14.29

All four of the above formulations presented excellent characteristics of adhesiveness.

10

EXAMPLE 4**Formulation 8**

Composition of the matrix

Eudragit E	10.5	G
Water	49.2	G

11

Lauric acid	6.2	G
Adipic acid	1.2	G
Glycerine	6.9	G
Polyvinyl pyrrolidone 33000 (PVP)	5.2	G
Water	20.8	G

Process of fabrication***Solution A***

Eudragit E, lauric acid and adipic acid were dispersed in water at 80°C in vacuum conditions and under propeller stirring at a speed of 100 rpm for 60 minutes. The temperature was then brought down to 60°C, and glycerine was added. The resulting system was kept under stirring at the same speed for a further 15 minutes and then left to stand up to complete removal of any air that might have been entrapped.

Solution B

The PVP was added slowly to the water preheated at 50° and kept under stirring with a magnetic stirrer up to complete solubilization. Any water that might have evaporated was restored.

Solutions A and B were mixed at room temperature with a propeller stirrer until a homogeneous solution was obtained.

Formulation 8 resulting from the above process presented excellent characteristics of adhesiveness.

EXAMPLE 5**Comparison formulations**

Proceeding as described for Example 1, a series of comparison formulations, without the active ingredient and the polyvinylpyrrolidone, having the following compositions in grams were prepared:

Formulation	Eudragit L	Glycerine	PEG	NaOH	CMC	HPMC	HMC	PA	GA
9	30	19.6	45	5.4				0.9	
10	36.98	22.19	33.28	6.66					0.8
11	26.79	17.5	40.18	4.82	10.71				
12	26.1	17.05	39.14	4.7	13.01				
13	26.01	16.99	39.01	4.687		13.31			
14	27.15	17.74	40.72	4.89		9.51			
15	29.13	19.03	43.69	5.24		2.91			
16	26.01	16.99	39.01	4.68			13.31		

PEG = polyethylene glycol

CMC = carboxymethyl cellulose

HPMC = hydroxypropylmethyl cellulose

5 HMC = hydroxymethyl cellulose

PA = polyacrylate

GA = gum arabic

None of the formulations 9-16 were found to possess satisfactory characteristics
 10 of adhesiveness; i.e., they were either too sticky and hence hard to work or else
 too stiff and hence not suitable for ensuring adhesion to the skin.

EXAMPLE 6

The formulations referred to in Examples 1 and 2 underwent a skin-permeation
 15 test *in vitro* with human epidermis according to the procedure described in
 Minghetti P. *et al.*, J. Pharm. Pharmacol., 1999, 51:673-678, in comparison with
 commercially available products.

The results appear in the attached figures.

Figure 1 shows the permeation graph for Formulation 2 containing Flurbiprofen as
 20 compared to the commercial product Transact (The Boots Company). The straight
 lines indicating permeation for the two products are practically equivalent.

Figure 2 shows the permeation graph for Formulation 1 containing Ketoprofen as
 compared to the commercial product Fastum Gel (Menarini). The straight lines
 indicating permeation for the two products are practically equivalent.

Figure 3 shows the permeation graph of Formulation 3 containing sodium Diclofenac as compared to the commercial product Diclorem Tissugel (Alfa Wasserman). The straight lines indicating permeation for the two products are practically equivalent.

5

EXAMPLE 7

Composition of the polymeric systems used for the preparation of the matrices

Compo- Nents	Form. No. 1	Form. No. 2	Form. No. 3	Form. No. 4	Form. No. 5	Form. No. 6	Form. No. 7	Form. No. 8	Form. No. 9
Eudragit L	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5
Water	6.9	6.9	6.9	6.9	6.9	6.9	6.9	6.9	6.9
NaOH	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81	0.81
Water	6.61	9.6	11.95	7.99	10.34	5.87	8.19	4.26	8.1
PEG 400	5.41	8.09	8.09	8.09	8.09	5.41	5.41	5.41	6.75
Glycerine	2.36	3.52	3.52	2.36	2.36	3.52	3.52	2.36	2.94
PVP	1.8	2.7	1.8	2.7	1.8	2.7	1.8	2.7	2.25
Water	7.2	10.8	7.2	10.8	7.2	10.8	7.2	10.8	9

10 Preparation

Solution A

Eudragit L 100 was dispersed in water under propeller stirring at a speed of 100 rpm for 10 minutes. A solution of sodium hydroxide was prepared apart.

The solution of sodium hydroxide was added as fast as possible to the suspension of Eudragit L 100, and the speed of the stirrer was increased gradually up to 200 rpm. After a homogeneous solution had been obtained (approximately 5 minutes), PEG 400 and glycerine were added. The resulting system was kept under stirring at the same speed for a further 15 minutes and then left to stand, up to complete removal of any air that might have been entrapped therein.

20 Solution B

The PVP was added very slowly to the water preheated at 50°C and kept under stirring with a mechanical stirrer up to complete solubilization. Any water that

might have evaporated was restored.

Solution B was added to solution A, and the dispersion obtained was kept under mechanical stirring for a further 30 minutes.

The resulting polymeric system was left to stand, up to complete removal of any
5 air that might have been englobed therein, before being used.

Backing layer: artificial silk

Protective film: siliconized paper

Spreading on the backing layer and drying of the matrix were performed with a Matis spreading machine - Model: LTE-S

10 Rate of spreading: 1m/min

Drying time: 15 min

Drying temperature: 50°C

Distance between knife and protective film: 300 µm

At the end of the drying process, the matrix dried on the backing layer was made to
15 adhere to the protective film.

EXAMPLE 8

Composition of the polymeric systems used for the preparation of the matrices

	Form. No. 2	Form. No. 3	Form. No. 4	Form. No. 5
Indomethacin	1.9	=	=	=
Ibuprofen	=	1.9	=	=
Naproxen	=	=	1.9	=
Pyroxicam	=	=	=	1.9
Eudragit L100	10.7	10.7	10.7	10.7
Water	16.4	16.4	16.4	16.4
Sodium hydroxide	1.9	1.9	1.9	1.9
Water	19.2	19.2	19.2	19.2
PEG 400	16.1	16.1	16.1	16.1
Glycerine	7.0	7.0	7.0	7.0
PVP	5.4	5.4	5.4	5.4
Water	21.4	21.4	21.4	21.4

Preparation

Solution A

Eudragit L 100 was dispersed in water under mechanical stirring at a speed of 100
5 rpm for 10 minutes. A solution of sodium hydroxide was prepared apart.

The solution of sodium hydroxide was added as fast as possible to the suspension
of Eudragit L 100, and the speed of the stirrer was increased gradually up to 200
rpm. After a homogeneous solution had been obtained (approximately 5 minutes),
PEG 400 and glycerine were added. The resulting system was kept under stirring
10 at the same speed for a further 15 minutes and then left to stand, up to complete
removal of any air that might have been entrapped therein.

Solution B

The PVP was added very slowly to the water preheated at 50°C and kept under
stirring with a mechanical stirrer up to complete solubilization. Any water that
15 might have evaporated was restored.

The active ingredient was added slowly to solution A, and the mixture was kept
under stirring until a homogeneous solution was obtained. At the end of the
process, solution B was added, and the dispersion obtained was stirred for a
further 30 minutes.

20 The resulting polymeric system was left to stand, up to complete removal of any
air that might have been englobed therein, before being used.

Backing layer : PVC or artificial silk or non-woven cotton fabric

Protective film: siliconized paper

Spreading on the backing layer and drying of the matrix were performed with a

25 Matis spreading machine - Model: LTE-S

Rate of spreading: 1m/min

Drying time: 15 min

Drying temperature: 60°C

Distance between knife and protective film: 300 µm

30 At the end of the drying process, the matrix dried on the backing layer was made to
adhere to the protective film.

EXAMPLE 9

Composition of the polymeric system used for the preparation of the matrix

	Pyroxicam	0.5
	Eudragit L	2.25
5	Water	3.45
	Sodium hydroxide	0.405
	Water	4.05
	PEG 400	3.375
	Glycerine	1.47
10	PVP	1.41
	Methanol	7.99
	Transcutol	2
	Polyhydroxylated castor oil	1
	PEG 400	0.9
15	Tween 80	0.4
	Eucalyptus oil	0.23

Preparation**Solution A**

Eudragit L 100 was dispersed in water under mechanical stirring at a speed of 100 rpm for 10 minutes. A solution of sodium hydroxide was prepared apart.

The solution of sodium hydroxide was added as fast as possible to the suspension of Eudragit L 100, and the speed of the stirrer was increased gradually up to 200 rpm. After a homogeneous solution had been obtained (approximately 5 minutes), PEG 400 and glycerine were added. The resulting system was kept under stirring at the same speed for a further 15 minutes and then left to stand, up to complete removal of any air that might have been entrapped therein.

Solution B

The PVP was added very slowly to the methanol and kept under stirring with a mechanical stirrer up to complete solubilization. Any methanol that might have evaporated was restored.

The PEG 400, Transcutol, polyhydroxylated castor oil, Tween 80, and active

ingredient were added slowly to solution B, and the mixture was kept under stirring until a homogeneous solution was obtained. At the end of the process, solution A and the eucalyptus oil were added, and the dispersion obtained was stirred for a further 30 minutes.

- 5 The resulting polymeric system was left to stand, up to complete removal of any air that might have been englobed therein, before being used.

Backing layer : PVC

Protective film: siliconized paper

Spreading on the backing layer and drying of the matrix were performed with a

- 10 Matis spreading machine - Model: LTE-S

Rate of spreading: 1m/min

Drying time: 15 min

Drying temperature: 50°C

Distance between knife and protective film: 300 µm

- 15 At the end of the drying process, the matrix dried on the backing layer was made to adhere to the protective film.

EXAMPLE 10

Composition of the polymeric system used for the preparation of the matrix

	Naproxen	0.2
20	Eudragit L	1.07
	Water	1.64
	Sodium hydroxide	0.19
	Water	1.92
	PEG 400	1.6
25	Glycerine	0.7
	PVP	0.54
	Methanol	2.16
	PEG 400	0.5
	Tween 80	0.1

- 30 Preparation

Solution A

Eudragit L 100 was dispersed in water under propeller stirring at a speed of 100 rpm for 10 minutes. A solution of sodium hydroxide was prepared apart.

The solution of sodium hydroxide was added as fast as possible to the suspension of Eudragit L 100, and the speed of the stirrer was increased gradually up to 200 rpm. After a homogeneous solution had been obtained (approximately 5 minutes), PEG 400 and glycerine were added. The resulting system was kept under stirring at the same speed for a further 15 minutes and then left to stand, up to complete removal of any air that might have been entrapped therein.

Solution B

The PVP was added very slowly to the methanol and kept under stirring with a mechanical stirrer up to complete solubilization. Any methanol that might have evaporated was restored.

The PEG 400, Tween 80, and active ingredient were added slowly to solution B, and the mixture was kept under stirring until a homogeneous solution was obtained. At the end of the process, solution A, and the dispersion obtained was stirred for a further 30 minutes.

The resulting polymeric system was left to stand, up to complete removal of any air that might have been englobed therein, before being used.

Backing layer: PVC

Protective film: siliconized paper

Spreading on the backing layer and drying of the matrix were performed with a Matis spreading machine - Model: LTE-S

Rate of spreading: 1m/min

Drying time: 15 min

Drying temperature: 50°C

Distance between knife and protective film: 300 µm

At the end of the drying process, the matrix dried on the backing layer was made to adhere to the protective film.

EXAMPLE 11

Composition of the polymeric system used for the preparation of the matrix

	Nifedipine	0.6
	Eudragit L	3.75
	Water	5.75
	Sodium hydroxide	0.675
5	Water	6.75
	PEG 400	5.625
	Glycerine	2.45
	PVP	1.88
	Methanol	7.52

10 *Preparation*

Solution A

Eudragit L 100 was dispersed in water under propeller stirring at a speed of 100 rpm for 10 minutes. A solution of sodium hydroxide was prepared apart.

15 The solution of sodium hydroxide was added as fast as possible to the suspension of Eudragit L 100, and the speed of the stirrer was increased gradually up to 200 rpm. After a homogeneous solution had been obtained (approximately 5 minutes), PEG 400 and glycerine were added. The resulting system was kept under stirring at the same speed for a further 15 minutes and then left to stand, up to complete removal of any air that might have been entrapped therein.

20 *Solution B*

The PVP was added very slowly to the methanol and kept under stirring with a mechanical stirrer up to complete solubilization. Any methanol that might have evaporated was restored.

25 The active ingredient was added to solution B, and the mixture was kept under stirring until a homogeneous solution was obtained. At the end of the process, solution A was added, and the dispersion obtained was stirred for a further 30 minutes.

The resulting polymeric system was left to stand, up to complete removal of any air that might have been englobed therein, before being used.

30	Backing layer:	PVC
	Protective film:	siliconized paper

Spreading on the backing layer and drying of the matrix were performed with a Matis spreading machine - Model: LTE-S

Rate of spreading: 1m/min

Drying time: 15 min

5 Drying temperature: 50°C

Distance between knife and protective film: 300 µm

At the end of the drying process, the matrix dried on the backing layer was made to adhere to the protective film.

EXAMPLE 12

10 Composition of the polymeric system used for the preparation of the matrix

	Fentanyl	1.56
	Eudragit L	2.25
	Water	3.45
	Sodium hydroxide	0.405
15	Water	4.05
	PEG 400	3.375
	Glycerine	1.47
	PVP	1.34
	Water	7.56

20 *Preparation*

Solution A

Eudragit L 100 was dispersed in water under mechanical stirring at a speed of 100 rpm for 10 minutes. A solution of sodium hydroxide was prepared apart.

The solution of sodium hydroxide was added as fast as possible to the suspension
25 of Eudragit L 100, and the speed of the stirrer was increased gradually up to 200 rpm. After a homogeneous solution had been obtained (approximately 5 minutes), PEG 400 and glycerine were added. The resulting system was kept under stirring at the same speed for a further 15 minutes and then left to stand, up to complete removal of any air that might have been entrapped therein.

30 *Solution B*

The PVP was added very slowly to the water preheated at 50°C and kept under

stirring with a mechanical stirrer up to complete solubilization. Any water that might have evaporated was restored.

The Fentanyl was added slowly to solution A, and the mixture was kept under stirring until a homogeneous solution was obtained. At the end of the process,
5 solution B was added, and the dispersion obtained was stirred for a further 30 minutes.

The resulting polymeric system was left to stand, up to complete removal of any air that might have been englobed therein, before being used.

Backing layer: PVC

10 Protective film: siliconized paper

Spreading on the backing layer and drying of the matrix were performed with a Matis spreading machine - Model: LTE-S

Rate of spreading: 1m/min

Drying time: 15 min

15 Drying temperature: 50°C

Distance between knife and protective film: 300 µm

At the end of the drying process, the matrix dried on the backing layer was made to adhere to the protective film.

EXAMPLE 13

20 Composition of the polymeric system used for the preparation of the matrix

Thiocolchicoside	1.56
Eudragit L	2.25
Water	3.45
Sodium hydroxide	0.405
25 Water	4.05
PEG 400	3.375
Glycerine	1.47
PVP	1.34
Ethanol	7.56

30 Preparation

Solution A

Eudragit L 100 was dispersed in water preheated at 50°C under mechanical stirring at a speed of 100 rpm for 10 minutes. A solution of sodium hydroxide was prepared apart.

The solution of sodium hydroxide was added as fast as possible to the suspension of Eudragit L 100, and the speed of the stirrer was increased gradually up to 200 rpm. After a homogeneous solution had been obtained (approximately 5 minutes), PEG 400 and glycerine were added. The resulting system was kept under stirring at the same speed for a further 15 minutes and then left to stand, up to complete removal of any air that might have been entrapped therein.

10 *Solution B*

The PVP was added very slowly to the ethanol and kept under stirring with a mechanical stirrer up to complete solubilization. Any ethanol that might have evaporated was restored.

The thiocolchicoside was added slowly to solution A, and the mixture was kept under stirring until a homogeneous solution was obtained. At the end of the process, solution B was added, and the dispersion obtained was stirred for a further 30 minutes.

The resulting polymeric system was left to stand, up to complete removal of any air that might have been englobed therein, before being used.

20 **Support:** PVC

Protective film: siliconized paper

Spreading on the backing layer and drying of the matrix were performed with a Matis spreading machine - Model: LTE-S

Rate of spreading: 1m/min

25 **Drying time:** 15 min

Drying temperature: 50°C

Distance between knife and protective film: 300 µm

At the end of the drying process, the matrix dried on the backing layer was made to adhere to the protective film.

30 **EXAMPLE 14**

Composition of the polymeric systems used for the preparation of the matrices

Components	Form. No. 1	Form. No. 2
Lidocaine	0.8	0.8
Eudragit L100		4.5
Eudragit L100-55	4.5	
Water	6.9	6.9
Sodium hydroxide		0.81
Potassium hydroxide	0.81	
Water	8.1	8.1
PEG 400	6.75	6.75
Glycerine	2.94	2.94
PVP	2.25	2.25
Ethanol	9	9

Preparation

Solution A

- 5 Eudragit L 100 or L 100-55 was dispersed in water under mechanical stirring at a speed of 100 rpm for 10 minutes. A solution of sodium hydroxide or potassium hydroxide was prepared apart.

The solution of sodium hydroxide or potassium hydroxide was added as fast as possible to the suspension of Eudragit L 100 or L 100-55, and the speed of the
10 stirrer was increased gradually up to 200 rpm. After a homogeneous solution had been obtained (approximately 5 minutes), PEG 400 and glycerine were added. The resulting system was kept under stirring at the same speed for a further 15 minutes and then left to stand, up to complete removal of any air that might have been entrapped therein.

Solution B

15 The PVP was added very slowly to the ethanol and kept under stirring with a mechanical stirrer up to complete solubilization. Any ethanol that might have evaporated was restored.

The active ingredient was added slowly to solution B, and the mixture was kept under stirring until a homogeneous solution was obtained. At the end of the process, solution A was added, and the dispersion obtained was stirred for a further 30 minutes.

- 5 The resulting polymeric system was left to stand, up to complete removal of any air that might have been englobed therein, before being used.

Backing layer PVC

Protective film: siliconized paper

Spreading on the backing layer and drying of the matrix were performed with a

- 10 Matis spreading machine - Model: LTE-S

Rate of spreading: 1m/min

Drying time: 15 min

Drying temperature: 50°C

Distance between knife and protective film: 300 µm

- 15 At the end of the drying process, the matrix dried on the backing layer was made to adhere to the protective film.

EXAMPLE 15

Composition of the polymeric systems used for the preparation of the matrix

Components	Form No. 1	Form No. 2	Form No. 3	Form No. 4	Form No. 5	Form No. 6	Form No. 7	Form No. 8	Form No. 9
Sodium Diclofenac	2.2	3.22	5.4	5.03	2.15	2.3	2.5	2.5	
Diclofenac epolamine									2.5
Eudragit L100	4.51	8.90	9.01	8.32	4.16				
Eudr. L100- 55						4.16	4.13	4.16	4.16
Water	9.59	18.89	19.18	23.5	11.71	23.5	12.01	9.86	9.86
Sodium hydroxide	0.60	1.19	1.20	1.11	0.56	1.11			

Potassium hydroxide							0.55	0.77	0.77
Water	5.4	10.71	10.80	9.99	5.04	9.99	4.95	6.93	6.93
PEG 400	6.76	15.82	13.52	9.33	4.67	9.33	6.24	6.19	6.19
Glycerine	2.94	5.81	5.89	5.43	2.72	5.43	2.72	2.70	2.70
PVP	1.8	3.57	3.6	3.32	1.66	0.9	1.35	1.35	1.35
Ethanol	8.65	18.91	17.7	16.13	8.06	5.1	6.9	6.9	6.9
Succinic acid	0.4	0.8	0.8	0.74	0.37	0.37	0.37	0.37	0.37
Polyhydroxylated castor oil	2	3.96	6.8	6.28		3.15	3.15	3.15	3.15
Span 80	0.2	0.39	0.41	0.38	0.19	0.17	0.17	0.17	0.17
Isopropyl Myristate	0.6	0.39	1.2	1.1	0.55	0.55	0.55	0.55	0.55
Propylene glycol		1.18	6.7	9.34	4.67	3.1	3.1	3.1	3.1

Preparation

Solution A

5 Eudragit L 100 or L 100-55 was dispersed in water under propeller stirring at a speed of 100 rpm for 10 minutes. A solution of sodium hydroxide or potassium hydroxide was prepared apart.

The solution of sodium hydroxide or potassium hydroxide was added as fast as possible to the suspension of Eudragit L 100 or L 100-55, and the speed of the stirrer was increased gradually up to 200 rpm. After a homogeneous solution had
 10 been obtained (approximately 5 minutes), PEG 400 and glycerine were added. The resulting system was kept under stirring at the same speed for a further 15 minutes and then left to stand, up to complete removal of any air that might have been entrapped therein.

Solution B

The PVP was added very slowly to the ethanol and kept under stirring with a mechanical stirrer up to complete solubilization. Any ethanol that might have evaporated was restored.

- 5 The following were added in order to solution B: succinic acid, polyhydroxylated castor oil, SPAN 80, isopropyl myristate, propylene glycol, and active principle. The mixture was kept under stirring until a homogeneous solution was obtained. At the end of the process, solution A was added, and the dispersion obtained was stirred for a further 30 minutes.

- 10 The resulting polymeric system was left to stand, up to complete removal of any air that might have been englobed therein, before being used.

Backing layer: PVC

Protective film: siliconized paper

Spreading on the backing layer and drying of the matrix were performed with a

- 15 Matis spreading machine - Model: LTE-S

Rate of spreading: 1m/min

Drying time: 15 min

Drying temperature: 50°C

Distance between knife and protective film: 300 µm

- 20 At the end of the drying process, the matrix dried on the backing layer was made to adhere to the protective film.

EXAMPLE 16

Composition of the polymeric systems used for the preparation of the matrices

	Form. No. 1	Form. No. 2	Form. No. 3	Form. No. 4
Ketoprofen	1.56			
Fentanyl		1.56		
Clonidine			1.56	
Thiocolchicoside				1.56

Eudragit E	12.6	12.6	12.6	12.6
Water	59.94	59.94	59.94	59.94
Lauric acid	7.56	7.56	7.56	7.56
Adipic acid	1.53	1.53	1.53	1.53
Glycerine	8.37	8.37	8.37	8.37
PVP	6.3	6.3	6.3	6.3
Water	25.2	25.2	25.2	
Ethanol				25.2

Preparation**Solution A**

Eudragit E, lauric acid and adipic acid were dispersed in water at 80°C under vacuum conditions and under mechanical stirring at a speed of 100 rpm for 60 minutes. The temperature was then brought down to 60°C, and glycerine was added. The resulting system was kept under stirring at the same speed for a further 30 minutes and then left to stand, up to complete removal of any air that might have been entrapped therein.

10 Solution B

The PVP was added very slowly to the water or ethanol and kept under stirring with a mechanical stirrer up to complete solubilization. Any water or ethanol that might have evaporated was restored.

Solutions A and B and the active ingredient were mixed at room temperature using a mechanical stirrer until a homogeneous solution was obtained.

Backing layer: PVC

Protective film: siliconized paper

Spreading on the Backing layer and drying of the matrix were performed with a Matis spreading machine - Model: LTE-S

20 Rate of spreading: 1m/min

Drying time: 15 min

Drying temperature: 50°C

Distance between knife and protective film: 300 µm

At the end of the drying process, the matrix dried on the Backing layer was made to adhere to the protective film.

EXAMPLE 17

Composition of the polymeric system used for the preparation of the matrix

5	Ketoprofen	1.6
	Eudragit L	12.02
	Water	18.43
	Sodium hydroxide	2.13
	Water	21.57
10	PEG 400	18.0
	Glycerine	7.87

Eudragit L 100 was dispersed in water under propeller stirring at a speed of 100 rpm for 10 minutes. A solution of sodium hydroxide was prepared apart.

The solution of sodium hydroxide was added as fast as possible to the suspension of Eudragit L 100, and the speed of the stirrer was increased gradually up to 200 rpm. After a homogeneous solution had been obtained (approximately 5 minutes), PEG 400 and glycerine were added. The resulting system was kept under stirring at the same speed for a further 15 minutes and then left to stand, up to complete removal of any air that might have been entrapped therein.

20 The active principle was added to the dispersion preheated at 40°C thus prepared, and the mixture was kept under stirring until complete solubilization of the Ketoprofen. The resulting polymeric system was left to stand, up to complete removal of any air that might have been englobed therein, before being used.

Backing layer:	PVC
25 Protective film:	siliconized paper

Spreading on the backing layer and drying of the matrix were performed with a Matis spreading machine - Model: LTE-S

Rate of spreading:	1m/min
Drying time:	15 min
30 Drying temperature:	50°C
Distance between knife and protective film:	300 µm

At the end of the drying process, the matrix dried on the backing layer was made to adhere to the protective film.

EXAMPLE 18

Composition of the polymeric system used for the preparation of the matrix

5	Ketoprofen	1.34
	Eudragit E	14.2
	Water	66.5
	Lauric acid	8.4
	Adipic acid	1.6
10	Glycerine	9.3

Preparation

Solution A

Eudragit E, lauric acid and adipic acid were dispersed in water at 80°C under vacuum conditions and under mechanical stirring at a speed of 100 rpm for 60
15 minutes. The temperature was then brought down to 60°C, and glycerine was added. The resulting system was kept under stirring at the same speed for a further 30 minutes and then left to stand, up to complete removal of any air that might have been entrapped therein.

The active principle was added to the dispersion preheated at 50°C thus
20 prepared, and the mixture was kept under stirring until complete solubilization of the Ketoprofen. The resulting polymeric system was left to stand, up to complete removal of any air that might have been englobed therein, before being used.

Backing layer: PVC

Protective film: siliconized paper

25 Spreading on the backing layer and drying of the matrix were performed with a Matis spreading machine - Model: LTE-S

Rate of spreading: 1 m/min

Drying time: 15 min

Drying temperature: 60°C

30 Distance between knife and protective film: 300 µm

At the end of the drying process, the matrix dried on the backing layer was made to

adhere to the protective film.

PEEL-STRENGTH TEST

A number of examples are provided in what follows regarding determination of the peel strength of the patches prepared.

- 5 Determination of the peel strength was in accordance with the PSTC 1 method.

The analysis was carried out one week after preparation of the patches in order to enable stabilization of the matrix.

- The test specimens, sized 2.5 x 20 cm, were applied, making sure that no air bubbles were formed, in the centre of the clean surface of the plate. When the patches were applied, care was taken not to exert an excessive force on the surface of contact, so as not to adversely affect the subsequent measurements. Then a constant strength of 20 N/cm was exerted by rolling a 5-kg roller three times in the direction of the length of the patch. The specimens thus prepared were left to rest for 10 minutes at 20°C. Peel strength was determined by applying the plate to an electronic load cell. The test was carried out using either a polyethylene plate or a steel plate.

Operating conditions:

- peel angle: 180°
- rate of tensile force: 300 mm/min

- 20 The peel strength is expressed in cN/cm; for each specimen, three determinations were made.

RESULTS OBTAINED USING A POLYETHYLENE PLATE

Ex. 7, Form. 1	5.2 ± 1.1	cN/cm
Ex. 7, Form. 2	57.8 ± 2.5	cN/cm
25 Ex. 7, Form. 3	88.8 ± 12.7	cN/cm
Ex. 7, Form. 4	66.8 ± 11.2	cN/cm
Ex. 7, Form. 5	29.7 ± 1.4	cN/cm
Ex. 7, Form. 6	11.7 ± 2.2	cN/cm
Ex. 7, Form. 7	17.8 ± 3.6	cN/cm
30 Ex. 7, Form. 8	1.8 ± 0.2	cN/cm
Ex. 7, Form. 9	51.6 ± 13.6	cN/cm

RESULTS OBTAINED USING A STAINLESS STEEL PLATE

Ex. 1, Form. 1	183.0 ± 16.0 cN/cm
Ex. 15, Form. 2	146.7 ± 31.0 cN/cm
Ex. 15, Form. 3	137.0 ± 11.1 cN/cm
5 Ex. 15, Form. 4	145.5 ± 16.5 cN/cm
Ex. 15, Form. 5	175.0 ± 11.1 cN/cm
Ex. 15, Form. 7	86.8 ± 11.9 cN/cm
Ex. 2, Form. 3	932.0 ± 13.0 cN/cm
Ex. 16, Form. 1	519.0 ± 3.0 cN/cm

10 SHEAR-STRENGTH TEST

A number of examples are provided in what follows regarding determination of the slip strength of the patches prepared.

The test specimens, sized 2.5 x 1.75 cm, were applied on plates of lapped aluminium, making sure that no air bubbles were formed and taking care not to
15 exert an excessive force on the surface of contact, so as not to adversely affect the subsequent measurements. Then a constant strength of 20 N/cm was exerted on the surface of the specimen adhered to the plate, by rolling a 2.5-kg roller over it three times.

The specimen prepared was placed in a special structure that enabled an
20 inclination of the plates of 2° with respect to the vertical position, so that the rear part of the panel formed an angle of 178° with the free end part of the specimen, to which a weight of 500 g was applied.

The strength was measured in terms of time necessary for the entire surface to be detached from the plate by slipping.

25 RESULTS

Ex. 6, Form. 1	164.4 ± 13 min.
Ex. 6, Form. 2	49.8 ± 1.6 min.
Ex. 6, Form. 3	4.0 ± 1.0 min.
Ex. 6, Form. 4	70.2 ± 8.9 min.
30 Ex. 6, Form. 5	20.0 ± 5.3 min.
Ex. 6, Form. 6	558.3 ± 4.4 min.

	Ex. 6, Form. 7	96.6 ± 6 min.
	Ex. 6, Form. 8	697.2 ± 42.4 min.
	Ex. 6, Form. 9	267.9 ± 20.1 min.
	Ex. 6, Form. 1	240.0 ± 0.3 min.
5	Ex. 2, Form. 3	4.2 ± 0.1 min.
	Ex. 16, Form. 1	3.2 ± 0.3 min.

PERMEABILITY TESTS

A number of examples are provided in what follows regarding permeation of the active ingredients vehicled, also in comparison with products already available on the market.

The tests for permeability through the skin were carried out using a modified Franz diffusion cell.

As compared to the original model, the Franz cell used underwent a number of modifications. These consisted in the modification of the diameter of the receiving chamber, which was kept constant and equal to the maximum diameter in order to improve efficiency of mixing of the solution.

All the tests were carried out using human skin obtained by surgical operation. The layer of epidermis was prepared by immersion of the skin in distilled water at 60±1°C for one minute and subsequent mechanical separation of the dermis. The separated part was dehydrated in a dryer (25% RH) and kept in aluminium foil at -20°C up to the moment of use. This layer was then re-hydrated by immersion in a physiological solution (0.9% sodium chloride), at room temperature, for 16 hours, before being mounted on the Franz cells.

The patch specimen, which had a diameter of 18 mm, was made to adhere accurately and with a slight pressure exerted on the corneal layer immediately prior to being positioned on the cell in such a way that the part containing the active ingredient was facing the bottom chamber, in close contact with the receiving phase. The top chamber of the cell was set over the patch, and the two parts were isolated by using a teflon tape and parafilm®. The aim was to limit the evaporation of the receiving phase, and the two parts were held tightly together using a metal vice. The samples were taken from the sampling door positioned

half-way up the cell, using 1-ml syringes. After each sampling, the receiving phase was re-integrated up to the same quantity. The sink conditions were maintained throughout the experiment. All the tests were conducted under a vertical laminar-flow hood.

5 **A) PERMEABILITY TEST OF FORMULATIONS NO. 1, NO. 3, NO. 6 OF EXAMPLE 8**

Operating conditions:

- temperature: $32 \pm 0.5^\circ\text{C}$
- area of release of patch: 0.636 cm^2
- 10 • receiving phase: phosphate buffer solution at pH 7.4, degassed and sterilized by filtration with a $0.22\text{-}\mu\text{m}$ filter, with water having a degree of purity for HPLC. Streptomycin sulphate was added to this solution as microbicidal agent.
- volume of receiving phase: approx. 5 ml exactly measured for each cell
- rate of stirring: maximum allowed by apparatus
- 15 • volume sampled: $200 \mu\text{l}$
- The samples were taken at pre-set intervals.

Result:

EXAMPLE 8	
Time	Form. No. 3 ($\mu\text{g}/\text{cm}^2$ of Ibuprofen)
1	26.97
2	44.66
3	67.82
4	89.27
5	105.62
6	120.92
7	139.99
8	155.13
24	384.64

B) PERMEABILITY TEST OF FORMULATION NO. 1 OF EXAMPLE 9*Operating conditions:*

- temperature: $32 \pm 0.5^\circ\text{C}$
- area of release of patch: 0.636 cm^2
- 5 • receiving phase: phosphate buffer solution at pH 7.4, degassed and sterilised by filtration with a $0.22\text{-}\mu\text{m}$ filter, with water having a degree of purity for HPLC. Streptomycin sulphate was added to this solution as microbicidal agent.
- volume of receiving phase: 5 ml exactly measured for each cell
- rate of stirring: maximum allowed by apparatus
- 10 • volume sampled: $200 \mu\text{l}$
- The samples were taken at pre-set intervals.

Result

Time	EXAMPLE 9	
	Form. No. 1 ($\mu\text{g}/\text{cm}^2$ of Pyroxicam)	Dexicam [®] gel ($\mu\text{g}/\text{cm}^2$ of Pyroxicam)
1	1.28	1.49
3	1.45	1.64
5	1.70	1.84
7	2.05	2.00
24	3.98	3.84

C) PERMEABILITY TEST OF FORMULATIONS NO. 3, NO. 4, NO. 5, NO. 7, NO. 8 OF EXAMPLE 15*Operating conditions:*

- temperature: $32 \pm 0.5^\circ\text{C}$
- area of release of patch: 0.636 cm^2
- receiving phase: physiological solution degassed and sterilized by filtration with
20 a $0.22\text{-}\mu\text{m}$ filter, with water having a degree of purity for HPLC. Sodium azide was added to this solution as microbicidal agent.
- volume of receiving phase: 5 ml exactly measured for each cell

- rate of stirring: maximum allowed by apparatus
- volume sampled: 200 μ l
- The samples were taken at pre-set intervals.

Result

EXAMPLE 15						
Time	Form. No. 3 (μ g/cm ² of Diclofenac)	Form. No. 4 (μ g/cm ² of Diclofenac)	Form. No. 5 (μ g/cm ² of Diclofenac)	Form. No. 7 (μ g/cm ² of Diclofenac)	Form. No. 8 (μ g/cm ² of Diclofenac)	Dicloream® Tissugel (μ g/cm ² of Diclofenac)
1	1.84	0.92	0.51	1.10	0.98	0.30
3	2.72	1.06	0.54	1.37	1.83	0.94
6	3.79	1.48	0.91	2.15	3.36	2.27
8	4.45	1.84	1.41	2.80	4.60	3.16
24	14.50	8.21	14.18	12.42	18.26	11.48

5

D) PERMEABILITY TEST OF FORM NO. 1, NO. 4 OF EXAMPLE 16*Operating conditions:*

- temperature: 32 \pm 0.5°C
- area of release of patch: 0.636 cm²
- 10 • receiving phase: phosphate buffer solution at pH 7.4, degassed and sterilized by filtration with a 0.22- μ m filter, with water having a degree of purity for HPLC. Streptomycin sulphate was added to this solution as microbicidal agent.
- volume of receiving phase: 5 ml exactly measured for each cell
- rate of stirring: maximum allowed by apparatus
- 15 • volume sampled: 200 μ l
- The samples were taken at pre-set intervals.

Result

Time	EXAMPLE 16		
	Form No. 1 ($\mu\text{g}/\text{cm}^2$ of Ketoprofen)	Form No. 4 ($\mu\text{g}/\text{cm}^2$ of thiocolchicoside)	Muscoril® ($\mu\text{g}/\text{cm}^2$ of thiocolchicoside)
1	0	0	0.72
3	0	0.49	0.83
5	0.24	0.58	0.86
7	1.64	0.89	0.97
24	5.55	3.2	1.8

E) PERMEABILITY TEST OF EXAMPLE 17 FORMULATION 1*Operating conditions:*

- temperature: $32 \pm 0.5^\circ\text{C}$
- area of release of patch: 0.636 cm^2
- receiving phase: phosphate buffer solution at pH 7.4, degassed and sterilized by filtration with a $0.22\text{-}\mu\text{m}$ filter, with water having a degree of purity for HPLC. Streptomycin sulphate was added to this solution as microbicidal agent.
- volume of receiving phase: 5 ml exactly measured for each cell
- rate of stirring: maximum allowed by apparatus
- volume sampled: $200 \mu\text{l}$
- The samples were taken at pre-set intervals.

Result

EXAMPLE 17	
Time	Form. No. 1 ($\mu\text{g}/\text{cm}^2$ of Ketoprofen)
1	3.33
2	4.44
3	6.27
4	7.41
5	7.74
6	8.08
7	8.22
24	16.69

F) PERMEABILITY TEST OF THE FORMULATION OF EXAMPLE 18*Operating conditions:*

- 5 • temperature: $32 \pm 0.5^\circ\text{C}$
- area of release of patch: 0.636 cm^2
- receiving phase: phosphate buffer solution at pH 7.4, degassed and sterilized by filtration with a $0.22\text{-}\mu\text{m}$ filter, with water having a degree of purity for HPLC. Streptomycin sulphate was added to this solution as microbicidal agent.
- 10 • volume of receiving phase: 5 ml exactly measured for each cell
- rate of stirring: maximum allowed by apparatus
- volume sampled: $200 \mu\text{l}$
- The samples were taken at pre-set intervals.

Result

EXAMPLE 18	
Time	Form. No. 1 ($\mu\text{g}/\text{cm}^2$ of Ketoprofen)
1	0.20
2	0.39
3	0.80
4	1.12
5	1.55
6	1.83
7	2.07
24	6.62

CLAIMS

1. A patch for local and transdermal administration of active ingredients having at least one anionic or electron-attracting group and pharmaceutically acceptable salts thereof comprising:
 - 5 a) a prevalently aqueous polymeric matrix containing said active ingredient, whose polymer is selected from the group consisting of:
 - a-1) an anionic copolymer of methacrylic acid with a methacrylate ester with a C_1 - C_{10} linear or branched alcohol,
 - a-2) a cationic copolymer of methacrylic acid with a C_1 - C_{10} linear or branched alcohol containing a tertiary aminic group, and a neutral methacrylate ester with a C_1 - C_{10} linear or branched alcohol,
 - 10 said polymeric matrix further containing:
 - a3) high molecular weight polyvinylpyrrolidone,
 - a4) a plasticizer,
 - 15 b) a backing layer onto which the matrix (a) is adhered to
 - c) a protective film removable at the moment of use, placed on said matrix (a).
2. A patch according to claim 1, wherein the anionic copolymer of type (a1) or cationic copolymer of type (a2) have an average molecular weight ranging from 80,000 to 500,000.
- 20 3. The patch according to anyone of claims 1 and wherein the anionic copolymer of type (a1) or cationic copolymer of type (a2) have an average molecular weight from 100,000 to 300,000.
4. The patch according to anyone of claims 1 – 3 wherein the copolymer (a1) is selected from the group consisting of the copolymer of methacrylic acid and methylmethacrylate and the copolymer of methacrylic acid and ethylmethacrylate.
- 25 5. The patch according to anyone of claims 1-3, wherein the copolymer of type (a2) is selected from the group consisting of: the copolymer of dimethylaminoethylmethacrylate with methylmethacrylate, the copolymer of dimethylaminoethylmethacrylate with butylmethacrylate, and mixtures thereof.
- 30 6. The patch according to claim 4 wherein methacrylic acid –methylmethacrylate

copolymer is used characterised by having a ratio of free carboxylic groups/ester groups being approximately 1:1 and an average molecular weight of 135,000.

7. The patch according to claim 4 wherein methacrylic acid -ethylmethacrylate
5 copolymer is used characterised by having the ratio of free carboxylic acid/ester groups is 1/1, and the average molecular weight of said copolymer is 250,000.
8. The patch according to claim 5 wherein a mixture of copolymer dimethylaminoethylmethacrylate - methylmethacrylate and copolymer
10 dimethylaminoethylmethacrylate - butylmethacrylate is used having an average molecular weight of 150,000.
9. The patch according to anyone of claims 1-8 wherein polyvinylpyrrolidone is used having an average molecular weight of: 335,000.
10. The patch according to anyone of claims 1-8 wherein polyvinylpyrrolidone is
15 used having an average molecular weight of: 1,100,000.
11. The patch according to anyone of claims 1-10 containing non-ionic and anionic surfactants.
12. The process according to anyone of claims 1-11 wherein the plasticizer is
20 selected from the group consisting of acetyltributyl citrate, tributyl citrate, glycerine, propylene glycol, polyethylene glycols (PEGs) of varying molecular weight, phthalates and triethyl citrate.
13. The patch according to anyone of claims 1-12, wherein the active ingredients
25 containing anionic groups or an electronattracting group is selected from the group consisting of a non steroidal antiinflammatory, a muscle relaxant, antihypertensive , analgesic, local anaesthetic, and antianginal drug.
14. The patch according to anyone of Claims 1-13 containing enhancers.
15. The patch according to Claim 14, wherein the enhancers are selected from
30 the group consisting of diethylenglycolmonoethylether, propylene glycol, polyethylene glycols, polyhydroxylated castor oil, unsaturated and saturated acids and esters thereof, polysorbates, polyoxyethylenalcohols and terpenes.
16. The patch according to anyone of claims 1-15, wherein the backing layer (b)

consists of woven fabric, non-woven fabric, polymeric film and foaming material.

17. The patch according to anyone of claims 1-16, containing from 1 to 15 wt% of active ingredient with respect to the matrix weight.
- 5 18. The patch according to Claim 17 containing from 2 to 6 wt% of active ingredient with respect to the matrix weight.
19. The patch according to anyone of claims 1-18 containing from 2 to 200 wt% of polyvinyl pyrrolidone with respect to the copolymer (a1) or (a2) weight .
20. The patch according to claim 19 containing from 30 to 100 wt% of polyvinyl
10 pyrrolidone with respect to the copolymer (a1) or (a2) weight.
21. The patch according to anyone of claims 1-20 in which the plasticizing agent is contained in an amount of 5-200 wt% with respect to the copolymer (a1) or (a2) weight.
22. The patch according to claim 8, wherein the surfactant is contained in an
15 amount of 0.1-100 wt% with respect to the copolymer (a1) or (a2) weight.
23. The patch according to anyone of claims 14 and 15 , wherein the enhancers are contained in an amount of 1-150 wt% with respect to the copolymer (a1) or (a2) weight.
24. A polymeric matrix containing an active ingredient having an anionic or an
20 electron attracting group, whose polymer is selected from the group consisting of:
- a) a prevalently aqueous polymeric matrix containing said active principle, whose polymer is selected from the group consisting of:
- a-1) an anionic copolymer of methacrylic acid with a methacrylate ester with a
25 C₁-C₁₀ linear or branched alcohol,
- a-2) a cationic copolymer of methacrylic acid with a C₁-C₁₀ linear or branched alcohol containing a tertiary aminic group, and a neutral methacrylate ester with a C₁-C₁₀ linear or branched alcohol,
said matrix further containing:
- 30 a-3) high molecular weight polyvinylpyrrolidone
a-4) a plasticizer.

25. A process for preparing the patch according to anyone of claims 1-23, comprising :

- i) preparing a prevalently aqueous solution of the copolymer (a1) or (a2)
- ii) adding the active ingredient to a prevalently aqueous solution of the
5 copolymer (a1) or (a2) containing the plasticizer (a4) or alternatively to
that of the polyvinylpyrrolidone (a3),
- iii) spreading and drying the mixture coming from step (ii) onto the
protective film (c)
- iv) adhering the matrix(a) with the protective film as obtained in step (iii), to
10 the backing layer (b).




FIGURE 1




FIGURE 2

Diclofenac Permeation




FIGURE 3

INTERNATIONAL SEARCH REPORT

Application No
PCT/EP 01/00870A. CLASSIFICATION OF SUBJECT-MATTER
IPC 7. A61K9/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 456 745 A (LIST HARALD ET AL) 10 October 1995 (1995-10-10)	1-25
X	examples 7,8,12,22,24	1-3,5, 8-10, 14-16, 19-21,23
X	WO 97 39741 A (NATHANSEN CHRISTINA ;HOECK ULLA (DK); KREILGARD BO (DK); PHARMACIA) 30 October 1997 (1997-10-30)	1-25
X	page 14-15, system 4 and 5	1-3,5, 10,12, 14,17, 19-21, 23,24

	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

19 June 2001

Date of mailing of the international search report

09/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040. Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Borst, M

INTERNATIONAL SEARCH REPORT

International Application No.

1047/EP 01/00870

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No. "
X	DATABASE WPI Section Ch, Week 199244 Derwent Publications Ltd., London, GB; Class A96, AN 1992-363069 XP002170006 - & JP 04 266818 A (SEKISUI CHEM IND CO LTD), 22 September 1992 (1992-09-22) abstract: example	1-25
X		1-4, 6, 7, 9, 12, 14-17, 24
A	VENKATRAMAN S ET AL: "Skin adhesives and skin adhesion - 1. Transdermal drug delivery systems" BIOMATERIALS, 6B, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, vol. 19, no. 13, June 1998 (1998-06), pages 1119-1136, XP004161374 ISSN: 0142-9612 page 1127, left-hand column, paragraph 4 page 1127, left-hand column, last paragraph - page 1127, right-hand column, paragraph 1 page 1127, right-hand column, paragraph 2	1-25
A	LIN SHAN-YANG ET AL: "The effect of plasticizers on compatibility, mechanical properties, and adhesion strength of drug-free Eudragit E films" PHARMACEUTICAL RESEARCH, US, NEW YORK, NY, vol. 8, no. 9, September 1991 (1991-09), pages 1137-1143, XP002107579 ISSN: 0724-8741 page 1137, paragraph "materials" table II	1-25

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

Application No
PCT/JP 01/00870

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5456745 A	10-10-1995	DE 3827561 C AT 145226 T CA 1336727 A DE 58909748 D EP 0355536 A ES 2097111 T GR 3022543 T JP 2074259 C JP 2088644 A JP 7091397 B	28-12-1989 15-11-1996 15-08-1995 19-12-1996 28-02-1990 01-04-1997 31-05-1997 25-07-1996 28-03-1990 04-10-1995
WO 9739741 A	30-10-1997	AU 2187197 A	12-11-1997
JP 4266818 A	22-09-1992	JP 3132837 B	05-02-2001